Industry Overview

Orexin receptor market was valued at $800.2 million in 2025 and is projected to reach $1,436.1 million by 2035, growing at a CAGR of 6.1% during the forecast period (2026-2035).  The global orexin receptor market is projected to experience sustained growth over the forecast period from 2026 to 2035, driven by increasing recognition of sleep and neuropsychiatric disorders worldwide. Rising prevalence of insomnia, anxiety, major depressive disorder, and related conditions has significantly expanded the demand for targeted therapeutics acting on orexin 1 and orexin 2 receptors. Continuous advancements in neuroscience research and drug development have strengthened the clinical pipeline, encouraging innovation in receptor-specific therapies. Favorable regulatory support and improved diagnostic awareness are further contributing to market expansion across developed and emerging economies. Strategic collaborations among pharmaceutical companies and research institutions are accelerating product development and commercialization efforts. Growing healthcare expenditure and enhanced access to specialized treatment options are also supporting revenue growth in this segment. Collectively, these factors are expected to sustain steady market expansion throughout the forecast horizon.

Market Dynamics

Advancements in Selective Orexin Receptor Antagonists

Ongoing progress in neuropharmacology has led to the development of highly selective orexin 1 and orexin 2 receptor antagonists, enhancing therapeutic precision and safety profiles. Pharmaceutical companies are increasingly investing in research programs aimed at improving efficacy while minimizing adverse effects associated with earlier sleep medications. The introduction of next-generation dual and single receptor modulators reflects a shift toward mechanism-based treatment strategies. Clinical trial activity remains robust, particularly in the management of insomnia and related sleep disorders. These advancements are strengthening the product pipeline and attracting strategic partnerships. As a result, innovation in receptor selectivity is emerging as a key growth driver within the global orexin receptor market.

Rising Prevalence of Sleep Disorders and Increased Healthcare Awareness

The global rise in sleep-related disorders, driven by lifestyle changes, stress, and aging populations, continues to stimulate demand for effective treatment options. Greater public awareness regarding the health consequences of untreated insomnia and related conditions has improved diagnosis and treatment rates. Healthcare systems are placing stronger emphasis on mental health and sleep management as part of comprehensive care strategies. This shift is encouraging higher prescription volumes for innovative therapies targeting orexin pathways. In parallel, expanding healthcare infrastructure in emerging economies is improving patient access to advanced medications. Collectively, these factors are reinforcing long-term expansion prospects for the global orexin receptor market.

Market Segmentation

• Based on the type, the market is segmented into orexin 1 receptor and orexin 2 receptor.
• Based on the application, the market is segmented into insomnia, anxiety, sleep disorders, major depressive disorder and other.

Orexin 2 Receptor Segment Holding the Dominant Position

The Orexin 2 receptor category accounts for the leading revenue contribution owing to its established therapeutic relevance in sleep regulation. Strong clinical validation and regulatory approvals for selective antagonists have reinforced physician confidence in this mechanism of action. Pharmaceutical manufacturers such as Merck & Co., Inc. and Eisai Co., Ltd. continue to expand their commercial portfolios within this segment. Growing patient preference for targeted insomnia therapies with improved safety profiles has strengthened prescription volumes. Ongoing lifecycle management strategies and post marketing studies are sustaining product visibility. Incremental innovation in formulation and dosing approaches further supports segment stability. As clinical familiarity increases, this category is expected to maintain its dominant market standing.

Major Depressive Disorder Application Demonstrating Accelerated Growth

The Major Depressive Disorder application segment is anticipated to witness the fastest expansion driven by increasing research into orexin modulation beyond sleep disorders. Emerging clinical evidence suggests potential benefits in mood stabilization and emotional regulation, encouraging broader therapeutic exploration. Several biotechnology firms are advancing early and mid-stage trials to assess efficacy in treatment resistant populations. Rising global prevalence of depressive conditions continues to expand the target patient base. Strategic collaborations between research organizations and industry participants are accelerating development timelines. Investors are demonstrating heightened interest in novel neuropsychiatric mechanisms, strengthening funding inflows. This combination of scientific progress and unmet clinical need positions the segment for rapid advancement in the coming years.

Regional Outlook

The global Orexin Receptor market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Emerging as a Strategic Growth Hub

North America maintains a prominent position due to its advanced clinical research ecosystem and strong presence of established pharmaceutical manufacturers. Continuous product innovation and active clinical development programs are accelerating regional expansion. Companies such as Merck & Co. and Eisai Co., Ltd. are strengthening their footprint through commercialization of novel insomnia therapies targeting orexin pathways. Rising awareness of sleep related conditions and improved diagnostic rates continue to support prescription growth. Favorable reimbursement structures and structured regulatory pathways further enhance market stability. Increasing collaborations between research institutions and industry participants are shaping recent development trends.

Asia Pacific Gaining Momentum through Expanding Healthcare Investment

Asia Pacific is registering notable progress supported by rising healthcare expenditure and improving access to specialty care services. Growing urban populations and heightened recognition of mental health conditions are driving therapeutic demand. Regional and multinational pharmaceutical firms are expanding clinical activities to capture untapped opportunities. Japan remains a key contributor owing to early adoption of innovative sleep therapies and active life sciences research. Strategic partnerships and licensing agreements are becoming more frequent across emerging economies. The combination of demographic shifts and policy support continues to create favorable conditions for sustained regional growth.

Market Players Outlook

The major companies operating in the global orexin receptor market include AbbVie Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, and Sanofi S.A. Market players are leveraging partnerships, collaborations, mergers and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In June 2025, Centessa Pharmaceuticals Plc announced that the US Food and Drug Administration cleared its investigational new drug application to initiate a Phase 1 clinical study of ORX142, a novel and selective OX2R agonist, in healthy volunteers. ORX142 expands Centessa’s multi-asset orexin franchise, complementing ongoing Phase 2 development of ORX750 and reinforcing its strategy to advance OX2R agonists across neurological and neurodegenerative indications.

• In May 2025, Eisai Co., Ltd. announced the launch of DAYVIGO (lemborexant) in China following regulatory approval, marking the first orexin receptor antagonist introduced in the country for the treatment of adults with insomnia. DAYVIGO is a dual orexin receptor antagonist that targets OX1R and OX2R to regulate the sleep–wake cycle, supporting improved sleep onset and maintenance.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global orexin receptor market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.